Adjuvant Systemic Chemotherapy with or without Bevacizumab in Patients with Resected Liver Metastases from Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|84|1|14-21

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.1, 2012-10, pp. : 14-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hepatic Arterial Infusion with Irinotecan, Oxaliplatin, and Floxuridine plus Systemic Chemotherapy as First-Line Treatment of Unresectable Liver Metastases from Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 480-484

Karger

Access to resources Recommend Favorite

FOLFOX as Adjuvant Chemotherapy after Curative Resection of Distant Metastases in Patients with Colorectal Cancer

By  

Oncology, Vol. 80, Iss. 1-2, 2011-06 ,pp. : 84-91

Karger

Access to resources Recommend Favorite

Efficacy of Oxaliplatin-Based Chemotherapy in Curatively Resected Colorectal Cancer with Liver Metastasis

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 175-183

Karger

Access to resources Recommend Favorite

A Successfully Resected Case of Recurrent Lung and Liver Metastases of Rectal Cancer Treated withXELIRI + Bevacizumab Therapy

By  

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-03 ,pp. : 143-147

Karger

Access to resources Recommend Favorite

Prospective evaluation of 18F‐fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases

By  

HPB, Vol. 17, Iss. 7, 2015-07 ,pp. : 644-650

John Wiley & Sons Inc

Access to resources Recommend Favorite